CD274 and non-small cell lung carcinoma: In evaluated patients with NSCLC, UC, and MEL, treatment response and survival were similar in patients identified as PD-L1–positive using either AI-powered or manual scoring, suggesting that the additional PD-L1–positive patients identified using AI-powered scoring had a similar treatment response and survival to those identified as PD-L1–positive by both methods.